Newormics is committed to improving public health by identifying neurotoxicity and developmental toxicity in compounds which people may be exposed to. We aim to reduce reliance on large animal testing by prioritizing the chemicals of concern requiring further study.
We also want to promote the use of C. elegans as an important model organism for studying disease and fundamental biology, by providing our technology to research labs and companies worldwide to make their own discoveries.
Newormics is a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models as well as in vitro 3D tissue organoids. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.
Newormics was co-founded in 2016 by Prof. Adela Ben-Yakar and Evan Hegarty and is a spinoff from the Ben-Yakar Lab in the Mechanical Engineering Department at the University of Texas at Austin. The technology was first developed to immobilize C. elegans for performing laser axotomy. However its usefulness to allow high-resolution imaging of large numbers of humanized disease-model worms quickly became apparent. Initial pilot studies were performed using a 96 well format vivoChip and customized microscope. These studies identified neuroprotective compounds in an Alzheimer's model worm, and in a separate study, compounds able to inhibit protein aggregation.
Newormics was founded to develop vivo<.em>Chip technology and C. elegans based chemical screening further, and provide these products and services to a wider market. The company has provided vivoChip and vivoCube systems to over 26 research institutions around the globe.